Abstract:Objective To investigate the correlation between platelet-derived microRNA-126 (miR-126) and antiplatelet responsiveness of ticagrelor in patients with acute coronary syndrome (ACS). Methods A total of 272 ACS patients who received stable antiplatelet treatment with ticagrelor in Chinese PLA General Hospital from January 2019 to January 2020 were recruited continuously. After three days of ticagrelor treatment, thromboelastography (TEG) was applied to detect the adenosine diphosphate (ADP) inhibition (ADP%) with platelet mapping for platelet reactivity. Then, 49 patients with high ADP% were assigned into high antiplatelet reactivity (HAPR) group, and 49 ones with low ADP% were into low antiplatelet reactivity (LAPR) group. Platelet RNA was extracted from peripheral blood samples to measured miR-126 expression by using quantitative polymerase chain reaction (qPCR). SPSS statistics 27.0 was used for data analysis. Data comparison between two groups was performed using t test, Wilcoxon rank sum test orχ2 test depending on data type. Pearson correlation analysis was performed to analyze the correlation between platelet miR-126 and ticagrelor antiplatelet reactivity. Results The HAPR group had significantly higher ADP% than LAPR group [94.50% (92.95%, 97.42%) vs 67.40% (57.00%, 75.05%)], and elevated platelet expression level of miR-126 [2.97 (0.16,31.37) vs 1.00 (0.17,3.31)] when compared with the LAPR group (P<0.001). Platelet miR-126 was positively correlated with ADP% after ticagrelor treatment (r=0.25; P=0.013). Conclusion Platelet miR-126 may affect ticagrelor antiplatelet reactivity in ACS patients.